1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Histopathological and epigenetic changes in myocardium associated with cancer therapy‐related cardiac dysfunction

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Aims

          Cancer therapy‐related cardiac dysfunction (CTRCD) is commonly reported, but its histopathology, mechanisms, and risk factors are not known. We aimed to clarify the histopathology and mechanisms of CTRCD to identify risk factors.

          Methods and results

          We performed myocardial histopathological studies on 13 endomyocardial biopsies from CTRCD patients, 35 autopsied cancer cases with or without cardiac dysfunction, and controls without cancer (10 biopsies and 9 autopsies). Cardiotoxicity risk scores were calculated based on medication; and patient‐related risk factors, fibrosis, and cardiomyocyte changes were scored; and p53 and H3K27ac histone modification were evaluated by histological score (H‐score). In the biopsy cases, all histopathological changes and the p53 evaluation were significantly higher in the CTRCD group than in the controls [p53 H‐score; 63 (9.109) vs. 33 (5.099), P < 0.05]. In patients with a short time between drug and disease onset (<4.2 years), fibrosis and p53 positively correlated ( r = 0.76, P < 0.05), and in those with late onset disease (>4.2 years), cellular abnormalities and p53 trended to a positive correlation and cardiotoxicity risk scores and p53 positively correlated ( r = 0.95, P < 0.05). A year after biopsy, the short‐term group had significant recovery of ejection fraction compared with the long‐term group ( P < 0.05). The CTRCD group had a significantly worse overall survival prognosis than the control group [hazard ratio 7.61 (95% confidence interval 1.30–44.6), P < 0.05]. Autopsy cases with cancer treatment also had a high grade of histopathological changes, with even more severe changes in patients with cardiac dysfunction, and had increased p53 and H3K27ac expression levels, compared with controls. H‐scores of p53 and H3K27ac showed a positive correlation in the CTRCD group in biopsy cases ( r = 0.62, P < 0.05) and a positive correlation in autopsy cases.

          Conclusions

          Our results indicate distinct morphological characteristics in myocardial histopathology associated with CTRCD. p53 and H3K27ac histone modification could be sensitive markers of CTRCD and suggest a mechanistic involvement of epigenetic changes.

          Related collections

          Most cited references35

          • Record: found
          • Abstract: not found
          • Article: not found

          2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines:  The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC).

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy.

            Three types of anthracycline-induced cardiotoxicities are currently recognized: acute, early-onset chronic, and late-onset chronic. However, data supporting this classification are lacking. We prospectively evaluated incidence, time of occurrence, clinical correlates, and response to heart failure therapy of cardiotoxicity.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found

              Doxorubicin Cardiomyopathy

              Established doxorubicin cardiomyopathy is a lethal disease. When congestive heart failure develops, mortality is approximately 50%. Extensive research has been done to understand the mechanism and pathophysiology of doxorubicin cardiomyopathy, and considerable knowledge and experience has been gained. Unfortunately, no effective treatment for established doxorubicin cardiomyopathy is presently available. Extensive research has been done and is being done to discover preventive treatments. However an effective and clinically applicable preventive treatment is yet to be discovered.
                Bookmark

                Author and article information

                Contributors
                konoue@naramed-u.ac.jp
                kpathol@naramed-u.ac.jp
                Journal
                ESC Heart Fail
                ESC Heart Fail
                10.1002/(ISSN)2055-5822
                EHF2
                ESC Heart Failure
                John Wiley and Sons Inc. (Hoboken )
                2055-5822
                23 June 2022
                October 2022
                : 9
                : 5 ( doiID: 10.1002/ehf2.v9.5 )
                : 3031-3043
                Affiliations
                [ 1 ] Department of Diagnostic Pathology Nara Medical University 840 Shijo, Kashihara Nara 643‐8522 Japan
                [ 2 ] Department of Cardiovascular Medicine Nara Medical University 840 Shijo Kashihara Nara 634‐8522 Japan
                [ 3 ] Department of Pathology Suzuka General Hospital 1275‐53 Yasuduka Suzuka Mie 513‐8630 Japan
                [ 4 ] Department of Pathology National Cerebral and Cardiovascular Center 6‐1 Kishibe‐Shimmachi Suita Osaka 564‐8565 Japan
                Author notes
                [*] [* ] Correspondence to: Kenji Onoue, Department of Cardiovascular Medicine, Nara Medical University, 840 Shijo, Kashihara, Nara, 634‐8522, Japan. TEL: +81‐744‐22‐3051; FAX: +81‐744‐22‐9726. Email: konoue@ 123456naramed-u.ac.jp

                Kinta Hatakeyama, Department of Pathology, National Cerebral and Cardiovascular Center, 6‐1 Kishibe‐Shimmachi, Suita, Osaka, 564‐8565, Japan. Tel: +81‐6‐6170‐1070 (ext.31222); Fax: +81‐6‐6170‐1956. Email: kpathol@ 123456naramed-u.ac.jp

                Article
                EHF214034 ESCHF-21-01122
                10.1002/ehf2.14034
                9715834
                35747987
                20f4522a-bd5f-4dda-bc71-b8076acfe12c
                © 2022 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

                History
                : 26 April 2022
                : 30 November 2021
                : 09 June 2022
                Page count
                Figures: 6, Tables: 2, Pages: 13, Words: 4653
                Funding
                Funded by: Ministry of Education, Culture, Sport, Science, and Technology, Japan
                Award ID: 21K06941
                Categories
                Original Article
                Original Articles
                Custom metadata
                2.0
                October 2022
                Converter:WILEY_ML3GV2_TO_JATSPMC version:6.2.1 mode:remove_FC converted:01.12.2022

                endomyocardial biopsy,epigenetics,histone acetylation,oncocardiology,p53

                Comments

                Comment on this article